Vasculitis & polymyalgia rheumatica
Immune checkpoint molecules performance in ANCA vasculitis
Authors' conclusion
Results in urine, SN and histology suggest IC pathway abolition during acute disease restored in remission and contribute to understand PD-1 axis's role in AAV proposing it as a new biomarker of disease activity.
Study context
- Population
- Patients with antibody-associated vasculitis (AAV): discovery cohort from the authors' centre and external validation cohort from another institutiondiscovery cohort
- Participants
- 88 patients
- Comparison
- AAV vs healthy controls
- Acuten = 42
- Remissionn = 46
- Outcome
- PD-1, PD-L1 and PD-L2 concentrations in serum, urine and cell culture supernatant of AAV and HC; PD-1 and PD-L1 expression in kidney biopsies
Methodological detailsdiscovery cohort, external validation cohort, multiplex assay, External validation cohort: 30 patients (acute=16, remission=14), PD-1 and PD-L1 expression analysed in six diagnostic kidney biopsies
- Discovery cohort
- External validation cohort
- Multiplex assay
- External validation cohort: 30 patients (acute=16, remission=14)
- PD-1 and PD-L1 expression analysed in six diagnostic kidney biopsies
Main finding
As reported in the abstract
Immune checkpoint (IC) molecules in AAV vs HC
- Inflammatory renal lesions had fewer PD-1-positive interstitial cells/staining intensity than sclerotic lesions
- Serum and urine findings confirmed in the validation cohort
- AAV vs healthy controls (HC): P < 0.0001
- AAV vs HC: P = 0.0075
- Acute vs Remission: P = 0.036
- AAV vs HC: stimulated group p=0.04
- AAV vs HC: unstimulated p=0.0074
- AAV vs HC: P = 0.007
- AAV vs HC: P < 0.0001
- Acute vs Remission: P = 0.0051
Original publication
Immune checkpoint molecules performance in ANCA vasculitis. RMD Open. Published 13 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →